Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia
- Giménez, N.
- Martínez-Trillos, A.
- Montraveta, A.
- Lopez-Guerra, M.
- Rosich, L.
- Nadeu, F.
- Valero, J.G.
- Aymerich, M.
- Magnano, L.
- Rozman, M.
- Matutes, E.
- Delgado, J.
- Baumann, T.
- Gine, E.
- González, M.
- Alcoceba, M.
- Terol, M.J.
- Navarro, B.
- Colado, E.
- Payer, A.R.
- Puente, X.S.
- López-Otín, C.
- Lopez-Guillermo, A.
- Campo, E.
- Colomer, D.
- Villamor, N.
- Erakutsi egile guztiak +
ISSN: 1592-8721, 0390-6078
Argitalpen urtea: 2019
Alea: 104
Zenbakia: 3
Orrialdeak: 576-586
Mota: Artikulua